SOLICITATION NOTICE
65 -- Whole-genome/exome/transcriptome sequencing of metastatic tumors using Illumina’s
- Notice Date
- 5/1/2015
- Notice Type
- Presolicitation
- NAICS
- 325413
— In-Vitro Diagnostic Substance Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02RC52559-83
- Archive Date
- 6/2/2015
- Point of Contact
- Gwennifer K. Epps, Phone: 240-276-5445, Terry Galloway, Phone: 240-276-5384
- E-Mail Address
-
eppsg@mail.nih.gov, gallowaytl@mail.nih.gov
(eppsg@mail.nih.gov, gallowaytl@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Center for Cancer Research (CCR), Surgery Branch (SB), on a sole source basis plans to procure Illumina's TruSeq RNA-Seq library prep kits and Mid/High output Flow cell kits from Illumina, Inc., 5200 Illumina Way, San Diego, CA 92122, USA. This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.106-1 (b)(2) and 13.501-(a)(1) using simplified acquisition procedures for commercial acquisitions. The Government contemplates only one award and will be made as a result of this solicitation. This will be awarded as a firm fixed price, Indefinite Delivery Indefinite Quantity (IDIQ) type contract. The period of performance of the IDIQ contract is for five (5)-years, from the date of award. The Associated North America Industry Classification Code (NAICS) 325413 with the Business Size Standard 500 employees. It has been determined there are no opportunities to acquire green products or services for this procurement. The Surgery Branch (SB), of the National Cancer Institute is a combined laboratory and clinical research unit devoted to the development of innovative cancer immunotherapies and their translation to the treatment of patients with cancer. Efforts run the gamut from basic studies of cancer immunology to the conduct of clinical immunotherapy trials for patients with metastatic cancer. The Illumina TruSeq RNASeq reaction kits and Mid/High-output Flow cell kits are used specifically the NEXTSeq500 high-throughput DNA sequencer that NCI has acquired for whole genome, whole exome and whole transcriptome analysis. The data generated on NCI's sequencer using these kits and flow cells is essential for carrying out ongoing high priority projects to identify mutated antigens recognized by patient tumor-reactive T cells. Identification of these targets provides the SB with powerful tools that were recently used to guide cancer immunotherapy for a patient with a gastrointestinal tumor. The utilization of NGS genomic and proteomic studies in the SB lab will be applied to the treatment of a large population of patients with a variety of malignancies. The unique qualities provided by Illumina, Inc is relevant to NCI, as the contractor is the only company that can fulfill the all requirements of this procurement in a cost effective and timely manner. Illumina's NextSeq 500 NGS sequencing platform enables researchers to perform multiple sequencing applications in one platform allowing for fast samples-to-results workflow in one piece of equipment. The NextSeq 500 system is capable of doing whole-genomes, whole-exomes, whole-transcriptomes, and many other analyses in a single run that takes ~29hrs compared to 72+hrs for other NGS platforms. Essentially this system will give NCI, at a read depth of 2 X 150bp, 100-200Gb worth of data which translates to roughly ~800 million paired-end reads in ~30hrs (High Output Kit). The whole-exome and whole-transcriptome project, which is a major focus of ongoing studies in the Surgery Branch to develop novel cancer therapies, has made exclusive use of Illumina technologies to identify somatically mutated gene products expressed by individual patient tumors. To date the SB have sequenced approximately 30 whole-exomes and 20 whole-transcriptomes using Illumina platforms. Additionally, NCI must have reagents that are compatible with the Illumina platforms for NGS. The acquisitions of these reagents from Illumina are critical to the ability to treat cancer patients in a more personalized approach, fitting with the mission statement of the NIH. Lastly, Illumina is the only company that can provide the NextSeq 500 sequencing platform flow cell kits, and TruSeq RNA Seq library prep kits, required by NCI to generate labeled libraries for whole-exome or whole-transcriptome analysis. Purchasing reagents from another company would be disruptive to the science. Therefore, NCI feels Illumina is the best contractor to have continuity in our studies to ensure precision and accuracy within our clinical trials and projects. This is not a solicitation for competitive quotations. However, if any interested party especially a small business, believes they can meet the above requirement, may submit a quote and statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. All questions, quote, and the capability statement must be received electronically (via email) to Ms. Gwennifer Epps, Contracting Officer, at ge50d@nih.gov in MS Word or Adobe Portable Document Format (PDF)by May 18, 2015 no later than 11:00 AM EST. No telephone calls or facsimiles will be accepted. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA), through sam.gov. No collect calls will be accepted. Please reference solicitation number N02RC52559-83 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02RC52559-83/listing.html)
- Place of Performance
- Address: National Cancer Institute, Rockville, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN03717424-W 20150503/150501234724-836733b34da0db384010ea324c3d8e86 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |